Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line? | Zendy

Helen Adderley | Zendy; Christoph Ackermann | Zendy; Raffaele Califano | Zendy

Open Access

Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?

Author(s) -

Helen Adderley,

Christoph Ackermann,

Raffaele Califano

Publication year - 2019

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2019.09.116

Subject(s) - erlotinib , bevacizumab , medicine , lung cancer , oncology , tyrosine kinase , chemotherapy , mutant , quality of life (healthcare) , first line , progression free survival , cancer research , epidermal growth factor receptor , cancer , biology , receptor , gene , biochemistry , nursing

EGFR tyrosine kinase inhibitors (TKIs) represent the standard of care for first-line treatment for patients with advanced EGFR mutant non-small cell lung cancer (NSCLC) with superiority in overall response rate (ORR), progression free survival (PFS) and quality of life compared to platinum-based chemotherapy (ChT) (1).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research